Cullinan Therapeutics, Inc. (CGEM)
9.06
-0.01
(-0.11%)
USD |
NASDAQ |
Nov 20, 11:01
Cullinan Therapeutics Cash from Investing (Quarterly) : 51.64M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 51.64M |
| June 30, 2026 | 40.68M |
| March 31, 2026 | 32.41M |
| December 31, 2025 | 22.39M |
| September 30, 2025 | 67.39M |
| June 30, 2025 | 53.40M |
| March 31, 2025 | 36.80M |
| December 31, 2024 | 15.96M |
| September 30, 2024 | 19.88M |
| June 30, 2024 | -185.11M |
| March 31, 2024 | 12.96M |
| December 31, 2023 | 51.47M |
| September 30, 2023 | -42.96M |
| June 30, 2023 | 12.11M |
| Date | Value |
|---|---|
| March 31, 2023 | 15.18M |
| December 31, 2022 | -28.61M |
| September 30, 2022 | -57.98M |
| June 30, 2022 | 300.85M |
| March 31, 2022 | 35.86M |
| December 31, 2021 | -15.86M |
| September 30, 2021 | -25.59M |
| June 30, 2021 | -153.67M |
| March 31, 2021 | -137.73M |
| December 31, 2020 | 11.44M |
| September 30, 2020 | -1.941M |
| June 30, 2020 | 11.97M |
| March 31, 2020 | -26.89M |
| December 31, 2019 | -35.38M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Climb Bio, Inc. | 6.40M |
| Oncolytics Biotech, Inc. | -0.0069M |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -158.35M |
| Anixa Biosciences, Inc. | -0.245M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -43.08M |
| Cash from Financing (Quarterly) | 1.062M |
| Free Cash Flow | -165.47M |
| Free Cash Flow Per Share (Quarterly) | -0.6669 |
| Free Cash Flow to Equity (Quarterly) | -43.02M |
| Free Cash Flow to Firm (Quarterly) | -43.08M |
| Free Cash Flow Yield | -28.07% |